8-K Announcements
6Material company update
May 8, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Mar 27, 2026·SEC
Nu Skin Enterprises, Inc.(NUS)Earnings, Financials & Key Ratios
NUS•NYSE
1.6× P/E·Price updated Jun 19, 2026
AboutNu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.Show more
- Revenue$1.49B-14.3%
- EBITDA$143M+275.0%
- Net Income$160M+209.3%
- EPS (Diluted)3.18+207.8%
- Gross Margin69.45%+1.8%
- EBITDA Margin9.64%+304.1%
- Operating Margin6.12%+169.9%
- Net Margin10.79%+227.5%
- ROE22%+210.5%
NUS Key Insights
Nu Skin Enterprises, Inc. (NUS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Healthy dividend yield of 4.7%
- ✓Trading at only 0.3x book value
- ✓Efficient asset utilization: 1.1x turnover
✗Weaknesses
- ✗Weak 3Y average ROE of 1.0%
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Sales declining 10.5% over 5 years
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NUS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NUS Price & Volume
Nu Skin Enterprises, Inc. (NUS) stock price & volume — 10-year historical chart
Loading chart...
NUS Growth Metrics
Nu Skin Enterprises, Inc. (NUS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-4.06%
5 Years-10.47%
3 Years-12.61%
TTM-14.17%
Profit CAGR
10 Years1.87%
5 Years-3.49%
3 Years15.2%
TTM241.45%
EPS CAGR
10 Years3.52%
5 Years-2.61%
3 Years15.39%
TTM237.15%
Return on Capital
10 Years12.87%
5 Years4.86%
3 Years-0.1%
Last Year7.85%
NUS Recent Earnings
Nu Skin Enterprises, Inc. (NUS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.14-6.7%
$0.15
Rev
$321M-2.8%
$330M
Q1 2026
Feb 12, 2026Metric
Actual
Est
EPS
$0.29-3.3%
$0.30
Rev
$370M-3.2%
$383M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.34+13.3%
$0.30
Rev
$364M-4.8%
$383M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.43+72.0%
$0.25
Rev
$386M+2.5%
$377M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.14vs $0.15-6.7% | $321Mvs $330M-2.8% |
| Q1 2026 | Feb 12, 2026 | $0.29vs $0.30-3.3% | $370Mvs $383M-3.2% |
| Q4 2025 | Nov 6, 2025 | $0.34vs $0.30+13.3% | $364Mvs $383M-4.8% |
| Q3 2025 | Aug 7, 2025 | $0.43vs $0.25+72.0% | $386Mvs $377M+2.5% |
Based on last 12 quarters of dataView full earnings history →
NUS Peer Comparison
Nu Skin Enterprises, Inc. (NUS) competitors in Beauty Services and Direct Selling — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 HLF | 1.23B | 11.90 | 5.41 | 0.89% | 4.67% | |||
 USNA | 348.47M | 18.88 | 32.55 | 8.28% | 1.16% | 1.84% | 0.02 | |
 NATR | 353.81M | 20.12 | 18.98 | 5.67% | 4.06% | 12.08% | 0.12 | |
 MED | 122.75M | 11.04 | -6.49 | -35.96% | -5.79% | -9.68% | 0.08 | |
 EL | 30.62B | 84.81 | -26.92 | -8.46% | -1.67% | -6.29% | 2.44 | |
 COTY | 1.72B | 1.95 | -4.43 | -3.68% | -9.26% | -14.13% | 1.07 | |
 IPAR | 3.17B | 99.09 | 18.91 | 2.49% | 13.46% | 18.37% | 0.20 | |
 ELF | 3.82B | 64.20 | 145.91 | 24.59% | 3.34% | 5.16% | 0.81 |
Compare NUS vs Peers
Nu Skin Enterprises, Inc. (NUS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NUS Income Statement
Nu Skin Enterprises, Inc. (NUS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 2.28B | 2.68B | 2.42B | 2.58B | 2.7B | 2.23B | 1.97B | 1.73B | 1.49B | 1.44B |
Revenue Growth % | 3.23% | 17.55% | -9.65% | 6.67% | 4.41% | -17.44% | -11.53% | -12.04% | -14.26% | -14.17% |
Cost of Goods Sold | 502.08M | 634.14M | 581.42M | 658.03M | 675.22M | 630.91M | 611.85M | 550.23M | 453.76M | 442.38M |
COGS % of Revenue | 22.03% | 23.67% | 24.02% | 25.49% | 25.05% | 28.35% | 31.07% | 31.77% | 30.55% | - |
Gross Profit | 1.78B▲ 0% | 2.04B▲ 15.1% | 1.84B▼ 10.1% | 1.92B▲ 4.6% | 2.02B▲ 5.0% | 1.59B▼ 21.1% | 1.36B▼ 14.9% | 1.18B▼ 12.9% | 1.03B▼ 12.7% | 998.9M▲ 0% |
Gross Margin % | 77.97% | 76.33% | 75.98% | 74.51% | 74.95% | 71.65% | 68.93% | 68.23% | 69.45% | 69.31% |
Gross Profit Growth % | 4.08% | 15.07% | -10.07% | 4.62% | 5.02% | -21.07% | -14.89% | -12.93% | -12.73% | - |
Operating Expenses | 1.5B | 1.73B | 1.57B | 1.67B | 1.79B | 1.48B | 1.31B | 1.33B | 940.52M | 917.37M |
OpEx % of Revenue | 65.93% | 64.7% | 64.93% | 64.54% | 66.27% | 66.67% | 66.48% | 76.98% | 63.33% | - |
Selling, General & Admin | 1.5B | 1.73B | 1.57B | 1.67B | 1.73B | 1.44B | 1.29B | 1.13B | 940.52M | 917.37M |
SG&A % of Revenue | 65.93% | 64.7% | 64.93% | 64.54% | 64.35% | 64.49% | 65.47% | 65.3% | 63.33% | - |
Research & Development | 22M | 23M | 0 | 23.3M | 27.2M | 0 | 22.6M | 13M | 0 | 10.8M |
R&D % of Revenue | 0.97% | 0.86% | - | 0.9% | 1.01% | - | 1.15% | 0.75% | - | - |
Other Operating Expenses | -8.92M | -21.19M | 0 | -23.3M | 24.67M | 48.49M | -2.81M | 189.36M | 0 | -1000K |
Operating Income | 274.48M▲ 0% | 240.86M▼ 12.2% | 267.43M▲ 11.0% | 257.56M▼ 3.7% | 233.99M▼ 9.2% | 110.85M▼ 52.6% | 48.27M▼ 56.5% | -151.59M▼ 414.0% | 90.88M▲ 160.0% | 81.53M▲ 0% |
Operating Margin % | 12.04% | 8.99% | 11.05% | 9.98% | 8.68% | 4.98% | 2.45% | -8.75% | 6.12% | 5.66% |
Operating Income Growth % | 18.77% | -12.25% | 11.03% | -3.69% | -9.15% | -52.63% | -56.46% | -414.05% | 159.95% | - |
EBITDA | 346.05M | 323.86M | 344.08M | 331.56M | 359.02M | 183.35M | 117.49M | -81.78M | 143.14M | 131.93M |
EBITDA Margin % | 15.18% | 12.09% | 14.22% | 12.84% | 13.32% | 8.24% | 5.97% | -4.72% | 9.64% | 9.15% |
EBITDA Growth % | 14.02% | -6.41% | 6.24% | -3.64% | 8.28% | -48.93% | -35.92% | -169.6% | 275.04% | 225.97% |
D&A (Non-Cash Add-back) | 71.56M | 83M | 76.65M | 73.99M | 125.02M | 72.51M | 69.22M | 69.81M | 52.26M | 50.4M |
EBIT | 274.48M | 311.55M | 267.43M | 257.56M | 243.46M | 102.46M | 133.76M | -148.64M | 90.88M | 79.19M |
Net Interest Income | 0 | 0 | 0 | 24K | 157K | -11.49M | -25.56M | -26.41M | -13.95M | -14.91M |
Interest Income | 0 | 0 | 19.2M | 13.12M | 11.16M | 10.38M | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 19.2M | 13.1M | 11M | 21.88M | 25.56M | 26.41M | 13.95M | 14.91M |
Other Income/Expense | -8.92M | -21.19M | -12.25M | -1.33M | -1.53M | -21.88M | -21.69M | -23.47M | 105.32M | -17.34M |
Pretax Income | 265.57M▲ 0% | 219.67M▼ 17.3% | 255.17M▲ 16.2% | 256.23M▲ 0.4% | 232.46M▼ 9.3% | 88.97M▼ 61.7% | 26.58M▼ 70.1% | -175.05M▼ 758.6% | 196.2M▲ 212.1% | 64.19M▲ 0% |
Pretax Margin % | 11.65% | 8.2% | 10.54% | 9.92% | 8.62% | 4% | 1.35% | -10.11% | 13.21% | 4.45% |
Income Tax | 136.13M | 97.78M | 81.62M | 64.88M | 85.19M | -15.81M | 17.98M | -28.46M | 35.99M | 9.67M |
Effective Tax Rate % | 51.26% | 44.51% | 31.99% | 25.32% | 36.65% | -17.77% | 67.66% | 16.26% | 18.35% | 15.06% |
Net Income | 129.44M▲ 0% | 121.89M▼ 5.8% | 173.55M▲ 42.4% | 191.35M▲ 10.3% | 147.27M▼ 23.0% | 104.78M▼ 28.9% | 8.6M▼ 91.8% | -146.59M▼ 1805.6% | 160.2M▲ 209.3% | 54.52M▲ 0% |
Net Margin % | 5.68% | 4.55% | 7.17% | 7.41% | 5.46% | 4.71% | 0.44% | -8.46% | 10.79% | 3.78% |
Net Income Growth % | -9.54% | -5.83% | 42.39% | 10.26% | -23.04% | -28.85% | -91.8% | -1805.57% | 209.28% | 241.45% |
Net Income (Continuing) | 129.44M | 121.89M | 173.55M | 191.35M | 147.27M | 104.78M | 8.6M | -146.59M | 160.2M | 54.52M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 2.36▲ 0% | 2.16▼ 8.5% | 3.10▲ 43.5% | 3.63▲ 17.1% | 2.86▼ 21.2% | 2.07▼ 27.6% | 0.17▼ 91.8% | -2.95▼ 1835.3% | 3.18▲ 207.8% | 1.10▲ 0% |
EPS Growth % | -7.45% | -8.47% | 43.52% | 17.1% | -21.21% | -27.62% | -91.79% | -1835.29% | 207.8% | 237.15% |
EPS (Basic) | 2.45 | 2.21 | 3.13 | 3.66 | 2.93 | 2.10 | 0.17 | -2.95 | 3.25 | - |
Diluted Shares Outstanding | 54.85M | 56.48M | 55.93M | 52.77M | 51.43M | 50.52M | 49.86M | 49.66M | 50.3M | 49.42M |
Basic Shares Outstanding | 52.81M | 55.17M | 55.52M | 52.3M | 50.19M | 50M | 49.71M | 49.66M | 49.29M | 48.2M |
Dividend Payout Ratio | 58.76% | 66.11% | 47.36% | 40.96% | 51.79% | 73.5% | 903.11% | - | 7.39% | - |
NUS Balance Sheet
Nu Skin Enterprises, Inc. (NUS) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 777.79M | 799.24M | 740.17M | 903.2M | 872.95M | 759.87M | 701.87M | 538.6M | 547.7M | 522.89M |
Cash & Short-Term Investments | 438.25M | 398.26M | 344.04M | 423.9M | 354.81M | 278.51M | 267.82M | 197.99M | 239.84M | 200.41M |
Cash Only | 426.4M | 386.91M | 335.63M | 402.68M | 339.59M | 264.73M | 256.06M | 186.88M | 238.63M | 198.65M |
Short-Term Investments | 11.85M | 11.35M | 8.41M | 21.22M | 15.22M | 13.78M | 11.76M | 11.11M | 1.21M | 1.75M |
Accounts Receivable | 33.2M | 53.28M | 50.38M | 63.37M | 41.3M | 47.36M | 72.88M | 50.78M | 39.54M | 45.01M |
Days Sales Outstanding | 5.32 | 7.26 | 7.6 | 8.96 | 5.59 | 7.77 | 13.51 | 10.7 | 9.72 | 12.23 |
Inventory | 253.45M | 295.82M | 275.89M | 314.37M | 399.93M | 346.18M | 279.98M | 190.24M | 178.64M | 178.6M |
Days Inventory Outstanding | 184.26 | 170.27 | 173.2 | 174.37 | 216.19 | 200.28 | 167.02 | 126.2 | 143.7 | 148.74 |
Other Current Assets | 18.4M | 22.51M | 24.51M | 25.27M | 32.43M | 39.33M | 37.1M | 51.39M | 89.67M | 98.87M |
Total Non-Current Assets | 812.08M | 895.21M | 1.03B | 1.05B | 1.03B | 1.06B | 1.1B | 930.32M | 857.62M | 853.91M |
Property, Plant & Equipment | 464.59M | 464.54M | 644.82M | 653.45M | 598.25M | 571.67M | 523.07M | 466.91M | 451.19M | 451.96M |
Fixed Asset Turnover | 4.91x | 5.77x | 3.75x | 3.95x | 4.51x | 3.89x | 3.76x | 3.71x | 3.29x | 3.17x |
Goodwill | 114.95M | 196.57M | 196.57M | 202.98M | 206.43M | 206.43M | 230.77M | 83.63M | 83.63M | 83.63M |
Intangible Assets | 67.65M | 89.99M | 80.32M | 89.53M | 76.99M | 66.7M | 105.31M | 74.28M | 42.61M | 39.29M |
Long-Term Investments | -33.78M | -37.33M | 0 | 11.34M | 35.87M | 39.49M | 40.11M | 39.59M | 18.75M | 18.75M |
Other Non-Current Assets | 164.9M | 144.11M | 76.34M | 61.16M | 89.51M | 87.03M | 99.81M | 91.67M | 261.44M | 279.04M |
Total Assets | 1.59B▲ 0% | 1.69B▲ 6.6% | 1.77B▲ 4.4% | 1.96B▲ 10.6% | 1.91B▼ 2.6% | 1.82B▼ 4.5% | 1.81B▼ 0.8% | 1.47B▼ 18.7% | 1.41B▼ 4.3% | 1.38B▲ 0% |
Asset Turnover | 1.43x | 1.58x | 1.37x | 1.32x | 1.41x | 1.22x | 1.09x | 1.18x | 1.06x | 1.02x |
Asset Growth % | 7.86% | 6.58% | 4.4% | 10.63% | -2.59% | -4.49% | -0.8% | -18.69% | -4.33% | -24.36% |
Total Current Liabilities | 447.37M | 439.65M | 356.76M | 542.86M | 529.69M | 359.24M | 328.87M | 296.61M | 263.73M | 257M |
Accounts Payable | 50.34M | 47.62M | 38.98M | 66.17M | 49.99M | 53.96M | 43.11M | 34.88M | 26.18M | 28.82M |
Days Payables Outstanding | 36.6 | 27.41 | 24.47 | 36.71 | 27.02 | 31.22 | 25.72 | 23.14 | 21.06 | 23.16 |
Short-Term Debt | 77.84M | 69.45M | 27.5M | 30M | 107.5M | 25M | 25M | 30M | 20M | 20M |
Deferred Revenue (Current) | 12.67M | 20.1M | 20.16M | 35.05M | 33.14M | 27.05M | 20.39M | 15.69M | 0 | 20.9M |
Other Current Liabilities | 103.73M | 99.63M | 3.9M | 137.97M | 3.51M | 3.36M | 68.79M | 23.89M | 191.76M | 201.98M |
Current Ratio | 1.74x | 1.82x | 2.07x | 1.66x | 1.65x | 2.12x | 2.13x | 1.82x | 2.08x | 2.03x |
Quick Ratio | 1.17x | 1.15x | 1.30x | 1.08x | 0.89x | 1.15x | 1.28x | 1.17x | 1.40x | 1.34x |
Cash Conversion Cycle | 152.98 | 150.12 | 156.32 | 146.63 | 194.76 | 176.82 | 154.81 | 113.76 | 132.36 | 137.82 |
Total Non-Current Liabilities | 437.91M | 472.92M | 536.96M | 519.95M | 464.01M | 564.43M | 655.62M | 520.85M | 336.34M | 325.71M |
Long-Term Debt | 310.79M | 361.01M | 334.46M | 305.39M | 268.78M | 377.47M | 478.04M | 363.61M | 261.83M | 203.59M |
Capital Lease Obligations | 0 | 9.33M | 105.7M | 120M | 94.08M | 88.68M | 80.39M | 66.69M | 63.99M | 242.22M |
Deferred Tax Liabilities | 36.72M | 32.62M | 27.86M | 23.36M | 24.16M | 35.97M | 522K | 39.87M | 310K | 310K |
Other Non-Current Liabilities | 127.12M | 102.58M | 68.93M | 71.2M | 77M | 62.31M | 96.67M | 50.68M | 10.22M | 68.1M |
Total Liabilities | 885.28M | 912.58M | 893.72M | 1.06B | 993.71M | 923.67M | 984.5M | 817.46M | 600.07M | 582.71M |
Total Debt | 388.63M | 430.46M | 507.01M | 500.38M | 503.79M | 520.52M | 607.33M | 478.23M | 364.25M | 277.61M |
Net Debt | -37.77M | 43.55M | 171.38M | 97.69M | 164.19M | 255.8M | 351.27M | 291.34M | 125.62M | 78.96M |
Debt / Equity | 0.55x | 0.55x | 0.58x | 0.56x | 0.55x | 0.58x | 0.74x | 0.73x | 0.45x | 0.35x |
Debt / EBITDA | 1.12x | 1.33x | 1.47x | 1.51x | 1.40x | 2.84x | 5.17x | - | 2.54x | 2.10x |
Net Debt / EBITDA | -0.11x | 0.13x | 0.50x | 0.29x | 0.46x | 1.40x | 2.99x | - | 0.88x | 0.60x |
Interest Coverage | - | - | 13.93x | 19.66x | 22.13x | 4.68x | 5.23x | -5.63x | 6.52x | 5.31x |
Total Equity | 704.6M▲ 0% | 781.87M▲ 11.0% | 875.29M▲ 11.9% | 894.27M▲ 2.2% | 912.77M▲ 2.1% | 897.3M▼ 1.7% | 821.97M▼ 8.4% | 651.46M▼ 20.7% | 805.24M▲ 23.6% | 794.09M▲ 0% |
Equity Growth % | 6.1% | 10.97% | 11.95% | 2.17% | 2.07% | -1.7% | -8.39% | -20.74% | 23.61% | 56.88% |
Book Value per Share | 12.85 | 13.84 | 15.65 | 16.95 | 17.75 | 17.76 | 16.49 | 13.12 | 16.01 | 16.07 |
Total Shareholders' Equity | 704.6M | 781.87M | 875.29M | 894.27M | 912.77M | 897.3M | 821.97M | 651.46M | 805.24M | 794.09M |
Common Stock | 91K | 91K | 91K | 91K | 91K | 91K | 91K | 91K | 91K | 91K |
Retained Earnings | 1.61B | 1.64B | 1.73B | 1.84B | 1.91B | 1.94B | 1.87B | 1.71B | 1.86B | 1.86B |
Treasury Stock | -1.3B | -1.33B | -1.32B | -1.46B | -1.53B | -1.57B | -1.57B | -1.56B | -1.58B | -1.56B |
Accumulated OCI | -66.32M | -79.93M | -85.29M | -64.77M | -73.9M | -86.51M | -100.01M | -124.76M | -116.11M | -236.75M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NUS Cash Flow Statement
Nu Skin Enterprises, Inc. (NUS) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 302.56M | 202.74M | 177.93M | 379.14M | 141.58M | 108.06M | 118.64M | 111.74M | 80.29M | 75.98M |
Operating CF Margin % | 13.28% | 7.57% | 7.35% | 14.68% | 5.25% | 4.86% | 6.02% | 6.45% | 5.41% | - |
Operating CF Growth % | 9.91% | -32.99% | -12.24% | 113.08% | -62.66% | -23.68% | 9.79% | -5.81% | -28.15% | -1185.66% |
Net Income | 129.44M | 121.89M | 173.55M | 191.35M | 147.27M | 104.78M | 8.6M | -146.59M | 160.2M | 54.52M |
Depreciation & Amortization | 71.56M | 83M | 76.65M | 73.99M | 76.32M | 72.51M | 70.92M | 69.81M | 52.26M | 50.4M |
Stock-Based Compensation | 19.31M | 26.61M | 9.91M | 24.06M | 23.19M | 12.37M | 15.65M | 14.82M | 24.11M | 14.8M |
Deferred Taxes | 39.21M | -14.93M | 1.97M | -11.91M | 5.82M | -51.63M | -18.09M | -55.48M | 20K | -5.7M |
Other Non-Cash Items | -4.06M | 58.05M | 48.29M | 49.09M | 82.6M | 62.71M | 123.25M | 257.51M | -86.69M | 48.2M |
Working Capital Changes | 47.09M | -71.88M | -132.44M | 52.56M | -193.62M | -92.67M | -81.68M | -28.34M | -69.62M | -86.24M |
Change in Receivables | -103K | -10.45M | 2.75M | -11.21M | 20.22M | -11.45M | -22.68M | -7.76M | 10.05M | 10.2M |
Change in Inventory | 7.54M | -33.37M | 18.45M | -31.14M | -95.32M | 40.31M | -13.22M | 30.32M | 11.89M | 6.04M |
Change in Payables | 6.83M | -9.16M | -7.18M | 24.84M | -13.28M | 9.26M | -10.08M | -7.29M | -9.11M | -4.92M |
Cash from Investing | -91.96M | -108.76M | -71.41M | -79.43M | -88.73M | -67.08M | -134.5M | -37.96M | 170.66M | -25.17M |
Capital Expenditures | -60.16M | -70.37M | -66.07M | -63.82M | -68.61M | -59.06M | -58.49M | -41.58M | -34.28M | -34.41M |
CapEx % of Revenue | 2.64% | 2.63% | 2.73% | 2.47% | 2.55% | 2.65% | 2.97% | 2.4% | 2.31% | 2.39% |
Acquisitions | -31.75M | -38.51M | -8.07M | -14.95M | -18.96M | 8.02M | -77.28M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -63K | 116K | 0 | 0 | 0 | -8.02M | 0 | 0 | 194.72M | 1M |
Cash from Financing | -159.57M | -116.71M | -154.79M | -245.17M | -104.7M | -99.5M | 10.73M | -133.18M | -202.4M | -56.51M |
Debt Issued (Net) | -36.23M | 29.9M | -69.45M | -28.21M | 38.13M | 25.58M | 96.8M | -112.89M | -170M | -16.24M |
Equity Issued (Net) | -71.73M | -69.56M | -825K | -144.33M | -80.42M | -70.05M | -8.45M | -2.06M | -21.95M | -21.96M |
Dividends Paid | -76.06M | -80.58M | -82.19M | -78.39M | -76.27M | -77.02M | -77.62M | -11.93M | -11.83M | -11.71M |
Share Repurchases | -71.73M | -69.56M | -825K | -144.33M | -80.42M | -70.05M | -13.01M | -2.06M | -20.04M | -20.05M |
Other Financing | 24.44M | 3.53M | -2.33M | 5.76M | 13.86M | 21.98M | 0 | -6.3M | 1.38M | -6.61M |
Net Change in Cash | 69.15M▲ 0% | -39.49M▼ 157.1% | -51.28M▼ 29.9% | 67.05M▲ 230.8% | -63.09M▼ 194.1% | -74.87M▼ 18.7% | -8.67M▲ 88.4% | -69.17M▼ 698.0% | 51.75M▲ 174.8% | -5.12M▲ 0% |
Free Cash Flow | 242.4M▲ 0% | 132.37M▼ 45.4% | 111.86M▼ 15.5% | 315.32M▲ 181.9% | 72.97M▼ 76.9% | 49.01M▼ 32.8% | 60.15M▲ 22.7% | 70.16M▲ 16.6% | 46.01M▼ 34.4% | 41.57M▲ 0% |
FCF Margin % | 10.64% | 4.94% | 4.62% | 12.21% | 2.71% | 2.2% | 3.05% | 4.05% | 3.1% | 2.88% |
FCF Growth % | 7.71% | -45.39% | -15.49% | 181.88% | -76.86% | -32.84% | 22.74% | 16.64% | -34.42% | -36.94% |
FCF per Share | 4.42 | 2.34 | 2.00 | 5.98 | 1.42 | 0.97 | 1.21 | 1.41 | 0.91 | 0.84 |
FCF Conversion (FCF/Net Income) | 2.34x | 1.66x | 1.03x | 1.98x | 0.96x | 1.03x | 13.80x | -0.76x | 0.50x | 0.76x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.7M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NUS Key Ratios
Nu Skin Enterprises, Inc. (NUS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 18.91% | 16.4% | 20.95% | 21.63% | 16.3% | 11.58% | 1% | -19.9% | 22% | 6.84% |
Return on Invested Capital (ROIC) | 29.61% | 24.21% | 21.43% | 18.95% | 16.96% | 7.46% | 3.11% | -10.75% | 7.28% | 7.03% |
Gross Margin | 77.97% | 76.33% | 75.98% | 74.51% | 74.95% | 71.65% | 68.93% | 68.23% | 69.45% | 69.31% |
Net Margin | 5.68% | 4.55% | 7.17% | 7.41% | 5.46% | 4.71% | 0.44% | -8.46% | 10.79% | 3.78% |
Debt / Equity | 0.55x | 0.55x | 0.58x | 0.56x | 0.55x | 0.58x | 0.74x | 0.73x | 0.45x | 0.35x |
Interest Coverage | - | - | 13.93x | 19.66x | 22.13x | 4.68x | 5.23x | -5.63x | 6.52x | 5.31x |
FCF Conversion | 2.34x | 1.66x | 1.03x | 1.98x | 0.96x | 1.03x | 13.80x | -0.76x | 0.50x | 0.76x |
Revenue Growth | 3.23% | 17.55% | -9.65% | 6.67% | 4.41% | -17.44% | -11.53% | -12.04% | -14.26% | -14.17% |
Related:NUS Dividend History·NUS Revenue History·NUS Price History·NUS P/E History·NUS Financial Ratios·NUS Institutional Holders
NUS SEC Filings & Documents
Nu Skin Enterprises, Inc. (NUS) SEC filings — annual & quarterly reports (10-K, 10-Q)
NUS Frequently Asked Questions
Nu Skin Enterprises, Inc. (NUS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nu Skin Enterprises, Inc. (NUS) reported $1.44B in revenue for fiscal year 2025. This represents a 112% increase from $678.6M in 1996.
Nu Skin Enterprises, Inc. (NUS) saw revenue decline by 14.3% over the past year.
Yes, Nu Skin Enterprises, Inc. (NUS) is profitable, generating $54.5M in net income for fiscal year 2025 (10.8% net margin).
Dividend & Returns
Yes, Nu Skin Enterprises, Inc. (NUS) pays a dividend with a yield of 4.69%. This makes it attractive for income-focused investors.
Nu Skin Enterprises, Inc. (NUS) has a return on equity (ROE) of 22.0%. This is excellent, indicating efficient use of shareholder capital.
Nu Skin Enterprises, Inc. (NUS) generated $41.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.